The effectiveness of Interferon-Ophthalmo, an antiviral and immunotropic drug, in the treatment of adenoviral ophthalmic infections

Adenoviral conjunctivitis (AVC) is treated with pathogenetically determined immunotropic drugs, the most commonly used of which are combined eye drops that include recombinant human interferon alpha-2b and diphenhydramine hydrochloride. In 2020, Russia registered the first domestic generic of the original, called Interferon-Ophthalmo eye drops. Purpose: to compare the effectiveness and safety of InterferonOphthalmo and the original interferon alpha-2b + diphenhydramine drug (Ophthalmoferon) in AVC patients. Material and methods. The study included 30 patients (60 eyes) aged 18–75 years with a clinically confirmed AVC, divided into the main group and the control group, each having 15 patients. The main group received Interferon-Ophthalmo, while the control group received Ophthamoferon. The treatment procedures were identical, with the follow-up period of 15 days. Clinical manifestations of AVC were assessed according to multiple parameters: complaints of eyelid edema, eye redness, lacrimation, itching, foreign body sensation, severity of conjunctival edema and hyperemia, follicular reaction in the lower conjunctival fornix, and hemorrhages. Results. The comparative assessment of the proportion of cases of clinical recovery, performed on the 7th and the 15th days of AVC therapy, confirms the same effectiveness of the two drugs. Conclusion. Interferon-Ophthalmo has a high clinical efficacy comparable with that of the original drug Interferon alpha-2b + Diphenhydramine and can be recommended for the treatment of patients with adenoviral ophthalmic infections.

1. Kaneko H., Aoki K., Ohno S., et al. Complete genome analysis of a novel intertypic recombinant human adenovirus causing epidemic keratoconjunctivitis in Japan. J. Clin Microbiol. 2011; Feb; 49 (2): 484–90. doi: 10.1128/JCM.01044-10

2. Jun Liu, Zhijie Li. Resident innate immune cells in the cornea. Front Immunology. 2021; 26 (12): 620284. doi: 10.3389/fimmu.2021.620284

3. Gu J., Su Q.Q., Zuo T.T, Chen Y.B. Adenovirus diseases: a systematic review and meta-analysis of 228 case reports. Infection. 2021; 49 (1): 1–13. doi: 10.1007/ s15010-020-01484-7

4. Lee J., Bilonick R.A., Romanowski E.G., Kowalski R.P. Seasonal variation in human adenovirus conjunctivitis: A 30-year observational study. Ophthalmic Epidemiol. 2018 ; 25 (5–6): 451–6. doi : 10.1080/09286586.2018.1509096

5. Vakhova E.S., Jani E.V. The general principles of managing severe forms of hyperergic adenoviral conjunctivitis. A clinical case. Russian ophthalmological journal. 2016; 9 (2): 64–8 (in Russian). https://doi.org/10.21516/2072-0076-2016- 9-2-64-68

6. Chigbu D.I., Labib B.A. Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist. 2018; 17; 11: 981–93. doi: 10.2147/ IDR.S162669

7. Labib B.A., Minhas B.K., Chigbu D.I. Management of adenoviral keratoconjunctivitis: Challenges and solutions. Clin. Ophthalmology. 2020; 17; 14: 837–52. doi: 10.2147/OPTH.S207976

8. Skevaki C.L., Galani I.E., Pararas M.V., Giannopoulou K.P., Tsakris A. Treatment of viral conjunctivitis with antiviral drugs. Drugs. 2011; 12; 71 (3): 331–47. doi: 10.2165/11585330-000000000-00000

9. Yani E.V., Seliverstova K.E. Features of the course of adenovirus ophthalmic infection in patients with systemic allergies. Medical advice. 2016; 19: 142–4 (in Russian).

10. Bikbov M.M., Malkhanov V.B., Babushkin A.E. Conjunctivitis: differential diagnosis and treatment. Moscow: April, 2015 (in Russian).

11. Neroev V.V., Vakhova E.S. Diseases of the conjunctiva. National Guide to Ophthalmology. GEОTAR-Media, 2017 (in Russian).

12. Maichuk D.Yu., Maichuk Yu.F. Oftalmoferon® — 15 years of wide application in the treatment and prevention of infectious eye diseases. 2017: 82–100 (in Russian).